Esizayo Research Facility

Spearheading COVID-19 research with Global Impact.

In the face of unprecedented challenges posed by the COVID-19 pandemic, Right to Care Research Esizayo has emerged as hub for clinical trials and studies in both infectious and non-infectious diseases. Through tireless dedication and a commitment to scientific excellence, Right to Care Research Esizayo has solidified its position as a leader, running multiple international and local trials and thereby driving forward breakthroughs in the battle against these conditions.

The clinic:

Right to Care Research Esizayo boasts facilities that provide an optimal environment for conducting clinical trials. Led by a team of highly skilled researchers, the clinic possesses the necessary infrastructure to undertake rigorous trials that contribute significantly to the scientific community’s understanding of both infectious and non-infectious diseases.

Global collaboration and partnerships:

Recognising the urgency of the global health crisis, Right to Care Research Esizayo has fostered collaborations and partnerships with renowned institutions, research organisations, and pharmaceutical companies from around the world. These collaborative efforts have enabled the clinic to conduct international trials that incorporate diverse patient populations and generate data with global implications.

Pioneering clinical trials:

Right to Care Research Esizayo has become a hub for running multiple international clinical trials, focusing on various aspects, ranging from vaccine development to treatment strategies. By actively participating in these trials, the clinic has played a crucial role in accelerating the evaluation and approval of potential therapeutics, vaccines and preventative measures for a host of health conditions, particularly those related to HIV and COVID-19 populations and generate data with global implications.

Vaccine development and efficacy studies:

Right to Care Research Esizayo’s research initiatives have significantly contributed to the global endeavour of developing effective COVID-19 vaccines. Through conducting clinical trials, the clinic has played a pivotal role in determining the safety, and efficacy of these vaccines, thereby facilitating their swift authorisation and distribution. The findings from these studies have not only impacted local communities here in South Africa, but have also provided valuable insights for global vaccination strategies.

Treatment strategies and innovative therapies:

Right to Care Research Esizayo remains at the forefront of investigating and refining treatment strategies for infectious diseases such as COVID-19, TB, HIV associated illnesses and Hepatitis C. By conducting clinical trials, the clinic has contributed to the identification and validation of novel therapies and treatment modalities for these conditions.

Beyond the realm of infectious diseases, Right to Care Research Esizayo is also working in the field of non-communicable diseases, to assist patients living with chronic conditions. One such study involves the trial of a new lipid lowering agent for those with high cholesterol.

All of these studies serve not only to improve patient outcomes but also to guide healthcare practitioners in delivering the most effective care to their patients.

Data analysis and public health recommendations:

Esizayo Research Site’s research goes beyond clinical trials. The facility also engages in comprehensive data analysis, offering valuable insights into the epidemiology, transmission patterns, and long-term effects of these viruses. By leveraging this data, the clinic has provided evidence-based recommendations to local health authorities, shaping public health priorities.

Over the past years, Right to Care Research Esizayo has made substantial contributions to vaccine development, treatment strategies, and public health initiatives in both infectious and non-infectious diseases.

Right to Care Research Esizayo’s unwavering dedication to scientific excellence and its commitment to improving global health outcomes have earned it a well-deserved reputation as centre for clinical trials.

As the world continues to navigate the challenges posed by COVID-19 and other health priorities, Right to Care Research Esizayo’s contributions are invaluable in shaping a brighter and healthier future for all.

Trials Conducted At Esizayo Research Site

MOVe-OUT Study

The MOVe-OUT Study tested an antiviral study medication in people who had tested positive for COVID-19.



The SCORPIO-HR ACTIV-2D trial examined the use of protease inhibitors in the treatment of COVID-19. The trial aimed to elucidate whether an protease inhibitors could help to resolve COVID-19 symptoms faster in those who tested positive for the virus.



The purposes of the Ensemble Study was to determine the efficacy and safety of the investigational vaccine, called Ad26.COV2.S.



STRIDE-7 is a clinical trial testing an investigational study vaccine (V116) to assess its ability to protect against pneumococcal disease. The study is testing the vaccine in adults living with HIV.



The MOVe-AHEAD Study looked to examine a trial medication aiming to prevent illness in people exposed to COVID-19.